Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses: 2010-2021

Historic Change in Accured Expenses for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $19.1 million.

  • Neurocrine Biosciences' Change in Accured Expenses rose 1691.67% to $19.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $56.8 million, marking a year-over-year increase of 111.15%. This contributed to the annual value of $29.0 million for FY2024, which is 54.90% down from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Change in Accured Expenses is $19.1 million, which was up 119.54% from $8.7 million recorded in Q3 2021.
  • Neurocrine Biosciences' Change in Accured Expenses' 5-year high stood at $41.7 million during Q4 2019, with a 5-year trough of -$16.6 million in Q1 2019.
  • Its 3-year average for Change in Accured Expenses is $11.5 million, with a median of $11.1 million in 2020.
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Change in Accured Expenses showed a top increase of 3,524.84% in 2017 and a maximum decrease of 195.14% in 2017.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Change in Accured Expenses stood at $16.2 million in 2017, then plummeted by 46.87% to $8.6 million in 2018, then spiked by 383.59% to $41.7 million in 2019, then plummeted by 102.88% to -$1.2 million in 2020, then soared by 1,691.67% to $19.1 million in 2021.
  • Its Change in Accured Expenses stands at $19.1 million for Q4 2021, versus $8.7 million for Q3 2021 and $18.0 million for Q2 2021.